High expression of maspin is associated with early tumor relapse in breast cancer

Human Pathology

Volumn 40, Issue 8, 2009, Pages 1143-1151

  Joensuu, Kristiina M ^a   Leidenius, Marjut H K ^a   Andersson, Leif C ^a   Heikkilä, Päivi S ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Breast cancer; Early tumor relapse; Immunohistochemistry; Maspin

Indexed keywords

ESTROGEN RECEPTOR; MASPIN; PROTEIN BCL 2; PROTEIN P53; SERINE PROTEINASE INHIBITOR;

ADULT; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RELAPSE; CELL NUCLEUS; CYTOPLASM; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL COUNT; CELL NUCLEUS; CYTOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOMA, B-CELL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; SERINE PROTEINASE INHIBITORS; SERPINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67650383460     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.02.006     Document Type: Article

References (36)

1. Zou Z., Anisowicz A., Hendrix M.J., et al. Maspin: a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263 (1994) 526-529
2. Sheng S., Carey J., Seftor E.A., Dias L., Hendrix M.J., and Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci U S A 93 (1996) 11669-11674
3. Zhang M., Sheng S., Maass N., and Sager R. mMaspin: the mouse homolog of human tumor suppressor gene inhibits mammary tumor invasion and motility. Mol Med 3 (1997) 49-59
4. Maass N., Teffner M., Rösel F., et al. Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast. J Pathol 195 (2001) 321-326
5. Umekita Y., Ohi Y., Sagara Y., and Yoshida H. Expression of maspin predicts poor prognosis in breast-cancer patients. Int J Cancer 100 (2002) 452-455
6. Umekita Y., and Yoshida H. Expression of maspin is upregulated during the progression of mammary ductal carcinoma. Histopathology 42 (2003) 541-545
7. Mohsin S.K., Zhang M., Clark G.M., and Allred D.C. Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol 199 (2003) 432-435
8. Zou Z., Gao C., Nagaich A.K., et al. p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 275 (2000) 6051-6054
9. Joensuu H., Pylkkänen L., and Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145 (1994) 1191-1198
10. Chen-Levy Z., Nourse J., and Cleary M.L. The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol 9 (1989) 701-710
11. Hockenbery D., Nunez G., Milliman C., Screiber R.D., and Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348 (1990) 334-336
12. Knowlton K., Mancini M., Creason S., Morales C., Hockenbery D., and Anderson B.O. Bcl-2 slows in vitro breast cancer growth despite its antiapoptotic effect. J Surg Res 76 (1998) 22-26
13. Zhang W., Shi H.Y., and Zhang M. Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins. BMC Cancer 5 (2005) 50
14. Pratt M.A., White D., Kushwaha N., Tibbo E., and Niu M.Y. Cytoplasmic mutant p53 increase Bcl-2 expression in estrogen receptor-positive breast cancer cells. Apoptosis 12 (2007) 657-669
15. Joensuu K., Heikkilä P., and Andersson L.C. Tumor dormancy: elevated expression of stanniocalcins in late relapsing breast cancer. Cancer Lett 265 (2008) 76-83
16. Elston C.W., and Ellis I.O. Assessment of histologic grade. In: Elston C.W., and Ellis I.O. (Eds). The breast Vol 13 (1998), Churchill Livingstone, New York 356-384
17. Solomon L.A., Munkarah A.R., Schimp V.L., et al. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol 101 (2006) 385-389
18. Sood A.K., Fletcher M.S., Gruman L.M., et al. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 8 (2002) 2924-2932
19. Marioni G., Blandamura S., Giacomelli L., et al. Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Histopathology 46 (2005) 576-582
20. Cao D., Zhang O., Wu L.S., et al. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Mod Pathol 20 (2007) 570-578
21. Lonardo F., Li X., Siddiq F., et al. Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer 51 (2006) 31-39
22. Vecchi M., Confalonieri S., Nuciforo P., et al. Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene 27 (2008) 2148-2158
23. Reddy K.B., McGowen R., Schuger L., Visscher D., and Sheng S. Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alfa transgenic mouse model. Oncogene 20 (2001) 6538-6543
24. Shi H.Y., Zhang W., Liang R., et al. Blocking tumor growth, and invasion by maspin in a syngeneic breast model. Cancer Res 61 (2001) 6945-6951
25. Sheng S. A role of novel serpin maspin in tumor progression: the divergence revealed through efforts to converge. J Cell Physiol 209 (2006) 631-635
26. Ferrucci P.F., Rabascio C., Gigli F., et al. A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer. Int J Oncol 30 (2007) 955-962
27. Elledge R.M., and Allred D.C. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 52 (1998) 79-98
28. Shimizu C., Fukutomi T., Tsuda H., et al. c-erb-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 73 (2000) 17-20
29. Poelman S.M., Heinmann R., Fleming G.F., Recant W.M., and Conzen S.D. Invariant p53 immunostaining in primary and recurrent breast cancer. Eur J Cancer 40 (2004) 28-32
30. Wang S.E., Narasanna A., Whitell C.W., Wu F.Y., Friedman D.B., and Arteaga C.L. Convergence of p53 and transforming growth factor beta (TGFbeta) signalling on activating expression of the tumor suppressor gene in mammary epithelial cells. J Biol Chem 282 (2007) 5661-5669
31. Lee M.J., Suh C.H., and Li Z.H. Clinicopathological significance of maspin expression in breast cancer. J Korean Med Sci 21 (2006) 309-314
32. Hojo T., Akiyama Y., Nagasaki K., et al. Association of maspin expression and its reverse correlation with mutant p53 in various tumors. Cancer Lett 171 (2001) 103-110
33. Zhang W., and Zhang M. Tissue microarray analysis of maspin expression and its reverse correlation with mutant p53 in various tumors. Int J Oncol 20 (2002) 1145-1150
34. Gasparini G., Barbareschi M., Doglioni C., et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1 (1995) 189-198
35. Le M.G., Mathieu M.C., Douc-Rsy S., et al. c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int J Cancer 84 (1999) 562-567
36. Neri A., Marrelli D., Roviello F., et al. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer. Breast Cancer Res Treat 99 (2002) 77-83